Search alternatives:
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
9241
Data Sheet 1_Detection of hemodynamic changes in a porcine lipopolysaccharide model of systemic inflammation using dynamic light scattering measurements of the microcirculation.pdf
Published 2025“…Both intervention groups showed a Hurst exponent decrease centrally at T2 and peripherally already at T1.…”
-
9242
Supplementary Material for: Preliminary efficacy, tolerability, and safety analysis of Darolutamide for metastatic castration‑resistant prostate cancer: a single-center, open-label...
Published 2024“…The median time to PSA50 in the Darolutamide group was 1.5 months (95%CI 0.2619- 0.9545), significantly lower than that in the placebo group (3.0 months [95%CI 1.048- 3.818], p= 0.0259); The median time to PSA90 in the experimental group was 4 months (95%CI 0.3094- 1.437), 2 months shorter than that in the placebo group (6.0 months [95%CI 0.6961- 3.232]).With the median follow-up of 6 months, , the median decrease in serum PSA was -81.8% (range -60.4 to -99.9%) in the Darolutamide group and -69.4% (range -50.3 to -89.6%) in the placebo group. …”
-
9243
Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF
Published 2024“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
-
9244
Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF
Published 2024“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
-
9245
Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF
Published 2024“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
-
9246
Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF
Published 2024“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
-
9247
Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF
Published 2024“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
-
9248
Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF
Published 2024“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
-
9249
Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF
Published 2024“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
-
9250
Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF
Published 2024“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
-
9251
Supplementary Material for: A comparative cross-sectional study of hair density, hair shaft diameter of different severities of anterior scalp marginal traction alopecia in women.
Published 2024“…With increasing severity of AMTA, there was a significant decrease in HD: Grade 1 had HD of 227.56/cm2 compared to 131.22/cm2 in grade 4 at the intertemporal area, p<0.001. …”
-
9252
Supplementary Figure 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Published 2025“…<p>Flow cytometry of immune cells from serially collected blood samples with evidence of significant decrease in circulating NK cells in: A) Metastatic renal cell carcinoma cohort. …”
-
9253
-
9254
Complementary conditioning measures in healthy subjects.
Published 2024“…<b>(I) Novelty</b> ratings significantly decreased from pre to post-conditioning (F<sub>(1,51)</sub> = 10.2, <i>P</i> = 0.002; post hoc CS<sup>-</sup>, <i>P</i> = 0.0001; post hoc CS<sup>+</sup>, <i>P</i> = 0.01) but similarly for both stimuli (F<sub>(1, 51)</sub> = 0.17, <i>P</i> = 0.7; Interaction: F<sub>(1, 51)</sub> = 1.1, <i>P</i> = 0.3). …”
-
9255
-
9256
-
9257
30-year trends in incidence of acute STEMI and NSTEMI in the Belgian Province of Luxembourg. A long-term follow-up of the MONICA-BELLUX registry
Published 2025“…</p><p>b) What this study adds</p><p>In a 30-year registry in Luxembourg using modern AMI definitions, overall, AMI incidence decreased significantly, primarily due to a 3.8-fold reduction in STEMI.…”
-
9258
Table 2_Promotion of physical activity-related health competence using digital workplace-based health promotion: a pilot study for office workers.docx
Published 2025“…The other sub-competences also increased, but not significantly. HEPA decreased after the intervention and at follow-up, but the decrease was not statistically significant.…”
-
9259
Table 3_Promotion of physical activity-related health competence using digital workplace-based health promotion: a pilot study for office workers.xlsx
Published 2025“…The other sub-competences also increased, but not significantly. HEPA decreased after the intervention and at follow-up, but the decrease was not statistically significant.…”
-
9260
Table 1_Promotion of physical activity-related health competence using digital workplace-based health promotion: a pilot study for office workers.docx
Published 2025“…The other sub-competences also increased, but not significantly. HEPA decreased after the intervention and at follow-up, but the decrease was not statistically significant.…”